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Abstract
A sensitive and fast high-performance liquid chromatography–diode-array detection assay was de-
veloped and validated for the simultaneous quantification of 5-(4-hydroxyphenyl)-5-phenylhydan-
toin (HPPH), phenytoin (PHT) and lamotrigine (LTG) in samples of cultured HepaRG cells.
Chromatographic separation of analytes and internal standard (IS) was achieved in ∼15 min on a
C18-column, at 35°C, using acetonitrile (6%), methanol (25%) and a mixture (69%) of water–triethyl-
amine (99.7:0.3, v/v; pH 6.0), pumped at 1 mL/min. The analytes and IS were detected at 215 or
235 nm. Calibration curves were linear with regression coefficients >0.994 over the concentration
ranges of 0.1–15 µg/mL for HPPH; 0.15–30 µg/mL for PHT and 0.2–20 µg/mL for LTG. The method
showed to be accurate (bias value of ±10.5 or ±17.6% in the lower limit of quantification, LLOQ)
and precise (coefficient variation ≤8.1 or ≤15.4% in the LLOQ), and the absolute recovery of the an-
alytes ranged from 62.5 to 96.9%. HepaRG cells have emerged as a very promising in vitromodel to
evaluate metabolic, drug interaction and/or pharmacokinetic studies, and this methodology will be
suitable to support subsequent studies involving the antiepileptic drugs PHT and LTG.
Introduction
The in vitro studies play a crucial role during the discovery of drug
candidates (1). In fact, the high-throughput approaches for the early
assessment of potential drug candidates are important tools, providing
a key direction in the choice of the most promising chemical series to
pursue (2). Hence, the need of early predictive data became essential
for the development of several in vitro approaches to study drug dis-
position and pharmacokinetic properties. Among these in vitro tools
are those which permit to assess the metabolite profiling and the
potential for cytochrome P450 (CYP) drug interactions in various
species, including human-based in vitro models (1, 3, 4). Undoubted-
ly, the CYP isoenzymes mediate the metabolism of the majority
of drugs available today. Actually, serious clinical drug–drug
interactions could be prevented by knowledge of the potential for in-
hibition and/or induction of CYP isoenzymes in early stages of drug
discovery programs. Even the regulatory authorities widely accept
the use of in vitro data for assessment of the potential for drug–drug
interactions in the development of new drugs (2). Accordingly, several
in vitro metabolism models have been developed and are now avail-
able to study the hepatic drug metabolism (5). However, it should
be highlighted that only those models that involve human liver cells
have the capacity to express the complete metabolic pathways similar
to what occurs in men (6, 7). Nevertheless, despite the primary human
hepatocytes are considered the “gold standard” model for these pur-
poses, some pitfalls that have to be taken into account (e.g., scarce
and erratic availability, poor stability of functions in culture, limited
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growth activity and life span) make them not as appropriate as would
be desired for high-throughput screening (5, 7–12). Hence, other mod-
els have been proposed as an alternative to primary human hepato-
cytes like the immortalized human hepatic tumor cell lines such as
HepG2, Huh-7 and HepaRG cells (8, 9, 13, 14). In fact, it is believed
nowadays that the development of HepaRG cells, a new human cell-
line derived from a hepatocellular carcinoma, constitutes a promising
achievement to improve the evaluation of hepatic drug metabolism
under in vitro conditions (8). Indeed, among several other advantages,
the HepaRG cell line possesses the metabolic capacity characteristic
of primary human hepatocytes and the indefinite proliferation proper-
ty of hepatoma cell lines, making them a useful in vitro tool to study
the hepatic kinetics of drugs and to foresee drug–drug interactions
(5, 15, 16).
Thus, aiming at evaluating the potential for drug–drug interactions
involving the antiepileptic drugs (AEDs) lamotrigine (LTG) and
phenytoin (PHT) (Figure 1), a rapid, simple, sensitive, accurate and
reliable analytical assay was herein developed, which enable the
quantitative determination of LTG, PHT and its main metabolite in
samples of cultured HepaRG cells. Although PHT is extensively
para-hydroxylated to the inactive metabolite 5-(4-hydroxyphenyl)-
5-phenylhydantoin (HPPH) (Figure 1), mainly through CYP2C9
and CYP2C19 isoenzymes, LTG undergoes extensive metabolism
to an inactive glucuronide metabolite (17). Therefore, this high-
performance liquid chromatography assay with diode-array detection
(HPLC–DAD) is a useful bioanalytical tool to support future in vitro
metabolic, drug interaction and/or pharmacokinetic studies in Hep-
aRG cell cultures incubated with PHT and/or LTG in the presence
of other chemical entities (e.g., new drug candidates) to be tested.
Experimental
Reagents and cells
PHT, HPPH and carbamazepine (CBZ), used as internal standard (IS),
were purchased from Sigma-Aldrich (St Louis, MO, USA). LTG was
gently provided by Bluepharma (Coimbra, Portugal). Methanol and
acetonitrile, both of HPLC gradient grade, were purchased from Fish-
er Scientific (Leicestershire, UK) and the ultra-pure water (HPLC
grade, >18 MΩ cm) was prepared by means of a Milli-Q water
apparatus from Millipore (Milford, MA, USA). Triethylamine was
acquired from Merck KGaA (Darmstadt, Germany), the 85% ortho-
phosphoric acid from Panreac Química SA (Barcelona, Spain) and
ethyl acetate were purchased from Fisher Scientific (Leicestershire,
UK). HepaRG cells (lot no. #48588) were obtained from Life Technol-
ogies—Invitrogen™ (through Alfagene, Portugal). The cell culture
components including Williams’ E medium, fetal bovine serum, hy-
drocortisone hemisuccinate, dimethyl sulfoxide and trypsin–EDTA
were purchased from Sigma-Aldrich (St Louis, MO, USA).
Stock solutions, calibration standards and quality control
samples
Stock solutions of PHT (30 mg/mL), HPPH (15 mg/mL) and LTG
(10 mg/mL) were individually prepared by dissolving the appropriate
amount of each compound in methanol. To obtain the corresponding
working solutions, the stock solutions were then adequately diluted in
water–methanol (50:50, v/v). Then, stock and working solutions of
the individual compounds were properly mixed to afford six com-
bined spiking solutions with final concentrations of 1.5, 3, 15, 60,
180 and 300 µg/mL for PHT, 1, 2, 5, 20, 80 and 150 µg/mL for
HPPH and 2, 4, 15, 50, 125 and 200 µg/mL for LTG. Each one of
these combined solutions was daily used for spiking aliquots of sup-
plemented Williams’ E medium to prepare six calibration standards in
the concentration ranges of 0.15–30 µg/mL for PHT, 0.1–15 µg/mL
for HPPH and 0.2–20 µg/mL for LTG. The stock solution of the IS
was also prepared in methanol (2 mg/mL), and the working solution
(200 µg/mL) was obtained after diluting an appropriate volume of the
stock solution with water–methanol (50:50, v/v). The stock, working
and combining solutions were stored at 4°C and protected from light,
with exception of the IS working solution which was daily prepared.
Quality control (QC) samples at three representative concentration
levels, representing the low (QC1), medium (QC2) and high (QC3)
ranges of the calibration curves, were independently prepared in
Figure 1. Chemical structures of HPPH, PHT, LTG and carbamazepine, which was used as internal standard (IS).
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supplemented Williams’ E medium. With this purpose, aliquots of
supplemented Williams’ E medium were spiked to attain final concen-
trations of 0.45, 15 and 27 µg/mL for PHT, 0.3, 7.5 and 13.5 µg/mL
for HPPH and 0.6, 10 and 18 µg/mL for LTG. One other QC sample
at the concentration of the lower limit of quantification (QCLLOQ) was
also prepared.
Apparatus and chromatographic conditions
Chromatographic analysis was carried out using an HPLC system
(Shimadzu LC-2010A HT Liquid Chromatography) coupled with a
DAD (Shimadzu SPD-M20A). All instrumental parts were automati-
cally controlled by LC solution software (Shimadzu, Kyoto, Japan).
The chromatographic separation of LTG, HPPH, PHT and IS was
carried out at 35°C on a reversed-phase LiChroCART® Purospher
Star column (C18, 55 mm× 4 mm; 3 µm particle size) purchased from
Merck KGaA (Darmstadt, Germany). An isocratic elution was applied
using acetonitrile (6%), methanol (25%) and a mixture (69%) of
water–triethylamine (99.7:0.3, v/v; pH 6.0), pumped at 1 mL/min.
The mobile phase was filtered through a 0.2-µm filter and degassed
ultrasonically for 15 min before use. The injection volume was 20 µL,
and the wavelengths of 215 and 235 nm were selected for detection of
the compounds.
Sample preparation and extraction
Each aliquot (200 µL) of supplemented Williams’ E medium was
added to 20 µL of IS working solution, 300 µL of acetonitrile and
1 mL of ethyl acetate. Then, this mixture was vortex-mixed for 30 s
and centrifuged at 13,500 rpm (3 min). The organic layer was trans-
ferred to a glass tube, being the aqueous layer re-extracted twice
more with ethyl acetate (1 mL each time) using the conditions previ-
ously described. The combined organic phases were evaporated to
dryness under a gentle nitrogen stream at 45°C and then reconstituted
with 100 µL of mobile phase. Finally, an aliquot (20 µL) of the final
sample was injected into the chromatographic system.
Method validation
The international accepted recommendations for bioanalytical meth-
od validation (18–20) were followed to the validation of the developed
method. Accordingly, the acceptance criteria proposed for specific
validation parameters including selectivity, linearity, precision, accu-
racy, limits of quantification and recovery were considered.
Selectivity
To reproduce in the best way what happens in the real metabolic and
pharmacokinetic studies, samples of supplementedWilliams’ Emedium
collected from cultured HepaRG cells were analyzed and compared
with samples of the simple supplemented Williams’ E medium. Under
real experimental conditions, HepaRG cells were maintained in the
Williams’ E medium supplemented with 10% fetal bovine serum,
100 IU/mL penicillin, 100 µg/mL streptomycin, 5 µg/mL insulin,
2 mM glutamine and 5 × 10−5 M hydrocortisone hemisuccinate during
15 days. Afterward, cells were then maintained in the same culture me-
dium but supplemented with 2% dimethyl sulfoxide (differentiation
medium) for >15 days to obtain differentiated HepaRG cell cultures.
In both phases, HepaRG cell cultures were maintained at 37°C in a hu-
midified air incubator with 5% CO2, and the medium was renewed
every 3 days. Subsequently, the differentiatedHepaRG cells were seeded
at a high density (4.5 × 105 cells/cm2) in 96-well plates and maintained
during 48 h. After this period, the cells were exposed to 200 µL of
supplemented Williams’ E medium for 12 h. The total volume of each
well was collected to an Eppendorf, and 300 µL of acetonitrile was
immediately added.
Calibration curve
The linearity of the developed method for each analyte (PHT, HPPH
and LTG) was evaluated in the concentration ranges previously de-
fined using calibration curves prepared with six spiked supplemented
Williams’ Emedium calibration standards and assayed on three differ-
ent days (n = 3). Calibration curves were constructed by plotting the
analyte–IS peak area ratio versus the corresponding nominal concen-
trations. The data were subjected to a weighted linear regression anal-
ysis using 1/x2 as weighting factor for all analytes, taking the plots and
the sums of absolute percentage of relative error into account. This
weighting factor yielded the best fit of peak area ratios versus concen-
tration for all compounds (21).
Limits of quantification
The lower limit of quantification (LLOQ) is defined as the lowest con-
centration of the calibration curve, which can be measured with ade-
quate inter/intraday precision and accuracy (18, 19). This parameter
was evaluated by analyzing supplemented Williams’ E medium sam-
ples prepared in replicates. The precision, expressed as percentage of
coefficient of variation (CV), cannot exceed 20%; whereas accuracy,
expressed by the deviation from nominal concentration value (bias),
must be within ±20%.
Precision and accuracy
To investigate the interday precision and accuracy of the assay, QC
samples analyzed on three consecutive days (n = 3) at the four concen-
tration levels (QCLLOQ, QC1, QC2 and QC3) representative of the
calibration range were used. On the other hand, the intraday precision
and accuracy were assessed analyzing five sets of the QC samples in a
single day (n = 5). Taking into account the acceptance criterion defined
by the bioanalytical method validation guidelines, the intra- and inter-
day precision (expressed as percentage of CV) must be ≤15% (or 20%
in the LLOQ) and intra- and interday accuracy (expressed as percent-
age of bias) must be within ±15% (or ±20% in the LLOQ) (18, 19).
Recovery
Three QC samples (QC1, QC2 andQC3) were used to test the absolute
recovery of the analytes from the samples submitted to the treatment
previously described in the “Sample preparation and extraction” sec-
tion. The recovery was calculated comparing the analytes’ peak areas
from extracted QC supplemented Williams’ E medium samples with
those obtained after direct injection of nonextracted solutions at the
same nominal concentrations (n = 5). Likewise, the calculation of the
ratio of IS peak areas in extracted samples and nonextracted solutions,
evaluated at the concentration used in sample analysis, was used to
define its absolute recovery.
Results
Method validation
The previously described chromatographic conditions enabled the
separation of HPPH, PHT and LTG in spiked supplementedWilliams’
E culture medium samples. The order of elution of the compounds was
the following: LTG, HPPH, PHT and CBZ (IS), with a running time of
15 min. Figure 2 shows the representative chromatograms of the anal-
ysis of blank and spiked supplemented Williams’ E culture medium
samples.
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Selectivity
Taking into account the chromatographic similarity of the blank sam-
ples of supplemented Williams’ E medium collected from cultured
HepaRG cells and those of simple supplementedWilliams’ E medium,
the latter was chosen as matrix to the development and validation of
this HPLC–DAD methodology.
Calibration curves and LLOQs
Over the concentration ranges established for all of the analytes (PHT,
HPPH and LTG), the calibration curves obtained in supplemented
Williams’ E culture medium were linear (r2≥ 0.994; Table I), showing
a consistent correlation between analyte–IS peak area ratios and the
corresponding nominal concentrations in supplemented Williams’ E
culture medium. Regarding the wide calibration range and to compen-
sate for heteroscedasticity, the calibration curves were subjected to
weighted linear regression analysis using 1/x2 as the weighting factor
for all analytes. The choice of this factor took into account the plots
and the sums of absolute percentage relative error as statistical criteria.
Table I summarizes the regression equations of the calibration curves
and the corresponding determination coefficients (r2) achieved for
each analyte. The LLOQs were experimentally defined as 0.1 µg/mL
for HPPH, 0.15 µg/mL for PHT and 0.2 µg/mL for LTG with accept-
able precision (CV≤ 15.4%) and accuracy (bias varied from −17.6 to
12.0%).
Precision and accuracy
Table II contains the data for intra- and interday precision and accu-
racy obtained from QC supplemented Williams’ E medium samples at
the four different concentration levels (QCLLOQ, QC1, QC2 and QC3).
It is worthy to mention that all of the data fulfilled the acceptance cri-
teria. Therefore, the overall inter- and intraday CV values ≤8.1% (or
15.4% in the QCLLOQ), and the overall inter and intraday bias values
ranging from−9.4 to 10.5% (or−17.6–12.0% in the QCLLOQ) clearly
demonstrate that the HPLC–DADmethod herein described is reliable,
accurate and reproducible.
Recovery
Five repeated analysis (n = 5) at the three concentration levels (QC1,
QC2 and QC3) for HPPH, PHT and LTG were used to determine
the overall absolute recovery of each analyte. Table III exhibits the ab-
solute recovery data. As noted, the absolute mean recoveries ranged
from 62.5 to 96.9% with CV values <10.9% for all analytes (PHT,
HPPH and LTG). On the other hand, the absolute recovery value of
the IS (CBZ) was 82.4% with a CV value of 9.9%.
Discussion
Epilepsy is a serious chronic neurological disorder affecting ∼50
million people worldwide (22–24). LTG and PHT are two AEDs com-
monly used in clinical practice. LTG has been widely used in epilepsy
treatment due to its broad spectrum of activity, and it is also effective
as a mood stabilizer agent (25, 26). In turn, the therapeutic value of
PHT could be attested by its inclusion in the World Health
Figure 2. Typical chromatograms of extracted supplemented Williams’ E medium samples obtained by the HPLC–DAD assay developed: blank supplemented
Williams’ E medium at 215 nm (A1) and 235 nm (A2) and supplemented Williams’ E medium spiked with the analytes at the lower limit of quantification of the
calibration ranges at 215 nm (B1) and 235 nm (B2). HPPH, 5-(4-hydroxyphenyl)-5-phenylhydantoin; IS, internal standard; LTG, lamotrigine; PHT phenytoin.
Table I. Mean Calibration Parameters Obtained for HPPH, PHT and
LTG in Supplemented Williams’ E Culture Medium (n = 3)
Analyte Calibration parameters
Concentration range (µg/mL) Equationa r2
HPPH 0.1–15 y = 0.01288x + 0.0001 0.995
PHT 0.15–30 y = 0.0248x + 0.0007 0.994
LTG 0.2–20 y = 0.0172x + 0.0016 0.997
ay represents the analyte–IS peak area ratio; x represents the analyte
concentration (µg/mL).
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Organization’s list of essential medicines, which contains the most im-
portant medication needed in a basic health system (27).
Even though interactions may occur under AED polytherapy reg-
imens, such drugs are commonly prescribed for long periods of time
making possible the cotherapy and, consequently, the occurrence of
drug–drug interactions with other kind of therapeutic agents used
for usual comorbidities (28, 29). Actually, several comorbid health
conditions are common among people with epilepsy, mainly psychiat-
ric disorders (e.g., depression, psychosis, attention deficit hyperactivi-
ty, anxiety and panic disorder), increasing the likelihood of
coprescription (24). This fact added to the narrow therapeutic index
of several AEDs and their marked effects on the activity of CYP isoen-
zymes (inhibition or induction) (28) make the patients with epilepsy
especially susceptible to complex and unpredictable pharmacokinetic
and also pharmacodynamic interactions (28, 30–32).
As it is well known, PHT is extensively involved in drug interac-
tions with other AEDs (felbamate, oxcarbazepine and valproic
acid), and also with many other drugs such as antidepressants (fluox-
etine, fluvoxamine, imipramine, paroxetine, sertraline, trazodone and
viloxazine), antimicrobials (chloramphenicol, fluconazole, isoniazid,
miconazole and sulfaphenazole), antineoplastic drugs (doxifluridine,
fluorouracil, tamoxifen and tegafur) and several compounds frommis-
cellaneous classes such as allopurinol, amiodarone, azapropazone,
cimetidine, chlorpheniramine, dextropropoxyphene, diltiazem, disul-
firam, omeprazole, tacrolimus and ticlopidine (28, 33). On the other
hand, although there are fewer interactions described in the literature
involving LTG, the AED valproic acid and the antidepressant sertra-
line have been found to increase its serum concentrations (28).
Nowadays, it is well recognized the value of the early identification
of potential drug interactions in the development process of new drug
candidates (34). In this context, in vitro methodologies are being in-
creasingly used during preclinical drug development for the prediction
of drug–drug interactions, providing useful data to extrapolate to
human (35–38). Indeed, several in vitro models have demonstrated
the ability to identify relevant drug interactions. For instance, the met-
abolic interactions between valproic acid and LTG (39), and those in-
volving the PHT and the selective serotonin reuptake inhibitors,
norfluoxetine or paroxetine (33), have been identified and studied in
in vitro conditions. Therefore, bearing in mind the valuable character-
istics of HepaRG cells, this in vitro model arises as a valuable tool to
foresee drug–drug interactions (5, 16).
Thus, bioanalysis emerged as a critical tool in the process of drug
discovery and development, being essential for pharmacokinetic/phar-
macodynamics characterization of a drug compound. In fact, a pleth-
ora of assays has been continuously developed for novel chemical
entities to support the various stages of discovery and development
programs, involving quantitative bioanalytical methods for the mea-
surement of parent compounds and their metabolites in several biolog-
ical samples (40, 41). However, the degree of development and quality
of the bioanalytical assays used tend to increase as the lead drug can-
didates progress to more advanced stages. Accordingly, the levels of
analytical acceptance criteria become stricter in the latter stages,
being the results confirmed by appropriate validation assays, which at-
test its reliability, robustness and accuracy (40–42). This aspect ex-
plains the scarcity of HPLC methodologies fully validated in the
literature to support in vitro studies. Notwithstanding, the HPLC–
DAD assay herein reported to quantify LTG, PHTand its mainmetab-
olite was extensively validated taking into account the international
criteria of the US Food and Drug Administration (FDA) and the Euro-
pean Medicines Agency (EMA) guidelines.
Apart from other methodologies like, for example, gas chromatog-
raphy (43), several HPLC assays have been developed for the simulta-
neous determination of PHTand LTG in human plasma or urine using
mainly DAD or ultraviolet detection (30, 44–50). For instance, a
HPLC–DAD assay, which enables the simultaneous quantification
of PHT and LTG in human plasma, has been previously developed
Table II. Inter- and Intraday Precision (% CV) and Accuracy (% bias) Values Obtained for HPPH, PHT and LTG in Samples of Supplemented
Williams’ E Culture Medium at the Concentrations of the Lower Limit of Quantification (*) and at the Low (QC1), Middle (QC2) and High (QC3)
Concentrations Representative of the Calibration Ranges
Analyte Nominal concentration (µg/mL) Interday Intraday
Precision (% CV) Accuracy (% bias) Precision (% CV) Accuracy (% bias)
HPPH 0.1* 1.8 12.0 15.4 0.6
0.3 3.3 1.5 0.5 1.5
7.5 3.6 −10.0 4.4 −9.2
13.5 4.7 −3.2 0.3 5.0
PHT 0.15* 7.9 −16.2 3.7 −17.6
0.45 3.6 0.1 1.9 −2.5
15 3.5 −9.4 4.3 −8.5
27 8.1 −1.3 0.4 10.5
LTG 0.2* 3.9 −4.1 3.9 1.2
0.6 4.1 −5.5 1.8 −0.2
10 3.2 −6.6 5.3 −3.8
18 6.1 1.8 0.2 1.8
CV, coefficient of variation; bias, deviation from nominal concentration value.
Table III.Absolute Recovery of HPPH, PHT and LTG in Supplemented







HPPH 0.3 85.8 ± 9.4 10.9
7.5 80.4 ± 3.9 3.9
13.5 62.5 ± 1.4 2.2
PHT 0.45 85.1 ± 8.9 10.5
15 80.1 ± 3.5 4.4
27 66.2 ± 3.4 5.2
LTG 0.6 96.9 ± 6.2 6.4
10 85.2 ± 2.3 2.7
18 82.4 ± 2.5 3.0
aMean ± standard deviation, n = 5.
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by our group (50). Nevertheless, the PHT metabolite (HPPH) was not
considered in such a bioanalytical assay; moreover, it is desirable the
availability of less expensive, faster and simpler analytical methodol-
ogies to support drug interaction screening studies, and thus, the mi-
croextraction by packed sorbent used therein for sample preparation
was not considered to be the most easy-to-use approach in this case.
On the other hand, although the differences in terms of selectivity
and sensitivity between DAD and mass spectrometry detectors used
by other authors are incontestable (51) for screening purposes, the cur-
rent technique employing a more accessible and cheaper DAD detec-
tor is considered to be appropriate. Taking also into account the LC–
MS-MSmethod published by Kadi et al. (51), which was developed to
the simultaneous determination of LTG and PHT in human plasma, it
is also evident that our HPLC–DAD assay requires a more environ-
mentally friendly chromatographic mobile phase because of the differ-
ent nature of the column stationary phase employed (reversed-phase
versus normal-phase liquid chromatography). Additionally, it should
not be neglected the lack of HPLC assays fully validated for the quan-
tification of LTG or/and PHT in culture media or even in supernatants
of cell cultures. Actually, the HPLC–DAD method herein described is
the first one, which permits the quantification of LTG, PHT and its
main metabolite in samples of cultured HepaRG cells. In fact, we in-
tended to develop a robust technique, which will provide results with a
high level of confidence that could be properly interpreted.
Conclusion
In recent years, HepaRG cells emerged as a very promising model to
evaluate the hepatic drug metabolism under in vitro conditions. Con-
sequently, analytical methodologies to support the studies conducted
with this model are extremely relevant. Thus, the reported HPLC–
DAD method, validated according to the international requirements
of EMA and FDA, will be suitable to support future metabolic, drug
interaction and pharmacokinetics studies involving PHT and LTG in
cultured HepaRG cells.
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